Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Suven gets patent for...

    Suven gets patent for CNS molecules from Canada, Hong Kong

    Written by savita thakur thakur Published On 2016-06-15T15:06:03+05:30  |  Updated On 15 Jun 2016 3:06 PM IST
    Suven gets patent for CNS molecules from Canada, Hong Kong

    New Delhi : Drug firm Suven Life Sciences has received a patent each from Canada and Hong Kong for molecules to be developed as drugs for treatment of various central nervous system disorders.


    The product patents are "valid through 2032 and 2030, respectively," Suven Life Sciences said in a filing to BSE.


    With these new patents, the company has a total of 23 patents from Canada and 20 patents from Hong Kong, it added.


    The new chemical entities (NCEs) are being developed for the treatment of cognitive impairment associated with neuro-degenerative disorders such as Alzheimer's disease, Parkinson and Schizophrenia, Suven Life Sciences said.


    "We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally," Suven CEO Venkat Jasti said.


    "The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents," Suven Life Sciences said.


    Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II, it added.


    Stock of Suven Life Sciences was trading at Rs 210.50 in the afternoon trade on BSE, up 1.54 per cent from the previous close.

    Alzheimer's diseasemoleculesNCEsneurodegenerationNew Chemical EntitiesParkinsonschizophreniaSuven Life SciencesVenkat Jasti
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok